Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

CAR-T (chimeric antigen receptor T cell) technology, which has recently showed successful
results in the treatment of hematological tumors, has been the focus of attention as one of …

CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of
patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy …

Chimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a
paradigm shift in personalized medicine as they can use and redirect the patient's immune …

Adoptive cell treatment (ACT) utilizing chimeric antigen receptors (CAR) diverts the
specificity of safe cells against a target-specific antigen and portrays exceptional potential for …

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Cancer immunotherapies utilize the capabilities of the immune system to efficiently target
malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed …

Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the
concept of treatment in hematological malignancies. In comparison with pediatric patients …

Chimeric antigen receptors (CARs) are fusion proteins with an extracellular antigen
recognition domain and numerous intracellular signaling domains that have been …

The clinical success stories of chimeric antigen receptor (CAR)-T cell therapy against B-cell
malignancies have contributed to immunotherapy being at the forefront of cancer therapy …